Intercure (INCR) - Total Assets
Based on the latest financial reports, Intercure (INCR) holds total assets worth ILA751.76 Million ILA (≈ $2.02 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See INCR book value for net asset value and shareholders' equity analysis.
Intercure - Total Assets Trend (2008–2024)
This chart illustrates how Intercure's total assets have evolved over time, based on quarterly financial data.
Intercure - Asset Composition Analysis
Current Asset Composition (December 2024)
Intercure's total assets of ILA751.76 Million consist of 51.4% current assets and 48.6% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 10.3% |
| Accounts Receivable | ILA180.50 Million | 23.7% |
| Inventory | ILA125.33 Million | 16.4% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA0.00 | 0.0% |
| Goodwill | ILA224.59 Million | 29.5% |
Asset Composition Trend (2008–2024)
This chart illustrates how Intercure's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see INCR company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Intercure's current assets represent 51.4% of total assets in 2024, an increase from 0.0% in 2008.
- Cash Position: Cash and equivalents constituted 10.3% of total assets in 2024, up from 0.0% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 29.0% of total assets, an increase from 0.0% in 2008.
- Asset Diversification: The largest asset category is goodwill at 29.5% of total assets.
Intercure Competitors by Total Assets
Key competitors of Intercure based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
|
China | CN¥21.15 Billion |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE
|
India | Rs93.93 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr67.43 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.02 Billion |
Intercure - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.85 | 1.78 | 2.28 |
| Quick Ratio | 1.12 | 1.15 | 1.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA172.03 Million | ILA161.94 Million | ILA45.14 Million |
Intercure - Advanced Valuation Insights
This section examines the relationship between Intercure's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.30 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | -3.1% |
| Total Assets | ILA762.57 Million |
| Market Capitalization | $37.38 Million USD |
Valuation Analysis
Below Book Valuation: The market values Intercure's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Intercure's assets decreased by 3.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Intercure (2008–2024)
The table below shows the annual total assets of Intercure from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ILA762.57 Million ≈ $2.04 Million |
-3.06% |
| 2023-12-31 | ILA786.61 Million ≈ $2.11 Million |
-17.89% |
| 2022-12-31 | ILA958.01 Million ≈ $2.57 Million |
+39.59% |
| 2021-12-31 | ILA686.32 Million ≈ $1.84 Million |
+110.35% |
| 2020-12-31 | ILA326.27 Million ≈ $874.72K |
+15.60% |
| 2019-12-31 | ILA282.23 Million ≈ $756.66K |
+685.73% |
| 2018-12-31 | ILA35.92 Million ≈ $96.30K |
+50.00% |
| 2017-12-31 | ILA23.95 Million ≈ $64.20K |
-13.66% |
| 2016-12-31 | ILA27.73 Million ≈ $74.35K |
+119.75% |
| 2015-12-31 | ILA12.62 Million ≈ $33.84K |
+378.04% |
| 2014-12-31 | ILA2.64 Million ≈ $7.08K |
-57.17% |
| 2013-12-31 | ILA6.16 Million ≈ $16.53K |
-57.57% |
| 2012-12-31 | ILA14.53 Million ≈ $38.95K |
+397.71% |
| 2011-12-31 | ILA2.92 Million ≈ $7.83K |
+121.66% |
| 2010-12-31 | ILA1.32 Million ≈ $3.53K |
-40.65% |
| 2009-12-31 | ILA2.22 Million ≈ $5.95K |
-87.61% |
| 2008-12-31 | ILA17.91 Million ≈ $48.01K |
-- |
About Intercure
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company has a strategic alliance with… Read more